Chiasma

Oral Therapeutic Options for Patients with Rare Diseases

Health Tech & Life Sciences
Acquired (Inactive) by Amryt Pharma Group on Aug 2021 - closed due to acquisition

Company Overview

Snapshot

Founded in April 2001, Chiasma operated with 11–50 employees and raised a total of $293.7 million across 10 funding rounds from 12 investors. The company was acquired by Amryt Pharma Group in August 2021, marking a significant exit for the biopharmaceutical firm.

Business overview

Chiasma was a clinical late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and debilitating diseases. The company leveraged its proprietary Transient Permeability Enhancer (TPE) technology platform to develop oral medications for treatments typically administered via injection. Chiasma focused on converting proteins, peptides, and small molecule drugs to oral delivery, serving the health tech and life sciences sectors, particularly in drug discovery and development for chronic and rare diseases.

Strategic signal

In June 2020, Chiasma received FDA approval for its MYCAPSSA (octreotide) capsules, providing a long-term maintenance treatment for acromegaly patients. This approval was a critical validation of Chiasma's TPE technology and its ability to deliver orally administered treatments for conditions previously requiring injections, signaling a significant advancement in patient care and market potential for oral biopharmaceuticals.

Company Intelligence Q&A

What was the most significant recent corporate event for Chiasma?
Chiasma was acquired by Amryt Pharma Group in August 2021. This acquisition led to Chiasma's delisting from NASDAQ.
When did Chiasma receive FDA approval for MYCAPSSA?
In June 2020, Chiasma received FDA approval for its MYCAPSSA (octreotide) capsules for the long-term maintenance treatment of acromegaly.
Did Chiasma conduct any public offerings?
Chiasma raised $102 million in a Nasdaq IPO in July 2015, with a valuation of $562 million. The company also had a public offering in April 2019.
What was the outcome of Chiasma's Phase III acromegaly trial?
In July 2019, Chiasma's Phase III acromegaly trial met all its endpoints, demonstrating the efficacy of its treatment.
Which investors participated in Chiasma's Series C funding round?
In November 2006, Chiasma secured Series C funding with participation from F2 Ventures.

External links